HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients
Stemming from preliminary results obtained by single cell-RNAseq we investigated by qPCR HSP and IFIT gene families in 27 LGLL patients (23 T-LGLL and 4 NK-LGLL), including 11 with neutropenia and/or thrombocytopenia and 16 asymptomatic for the disease. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1ß, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1ß, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1ß, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype. Overall design: Single cell samples of TLGLL patients peripheral blood: 2 Symptomatic T-LGLL patients with neutropenia, 2 asymptomatic T-LGLL gamma delta patients, 2 secondary patients that developed T-LGLL after being treated for B-NHL, 2 healthy controls.